FDA approves CYRAMZA® (ramucirumab) for EGFR-mutated non-small cell lung cancer
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
List view / Grid view
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
FDA approves Vimpat for partial-onset seizures in paediatric epilepsy patients as an oral solution or a convenient tablet...